Research models that replicate the diverse genetic and molecular landscape of breast cancer are critical for developing the next-generation therapeutic entities that can target specific cancer subtypes. Patient-derived tumorgrafts, generated by transplanting primary human tumor samples into immune-compromised mice, are a valuable method to model the clinical diversity of breast cancer in mice, and are a potential resource in personalized medicine. Primary tumorgrafts also enable in vivo testing of therapeutics and make possible the use of patient cancer tissue for in vitro screens. Described in this unit are a variety of protocols including tissue collection, biospecimen tracking, tissue processing, transplantation, and three-dimensional culturing of xenografted tissue, which enable use of bona fide uncultured human tissue in designing and validating cancer therapies. Curr. 
INTRODUCTION
Model systems are essential for discovery, development, and testing of new therapies for breast cancer. Generating the appropriate models for particular applications is challenging, as all models have both advantages and disadvantages. (Voskoglou-Nomikos et al., 2003; Gupta and Kuperwasser, 2004) . Immortalized cell lines are used routinely to study breast cancer, are easy to grow and manipulate, and are ideal for examining the molecular mechanisms of tumor cell biology (Burdall et al., 2003; Holliday and Speirs, 2011) . Likewise, implantation of breast cancer cell lines into mice for in vivo studies is a useful way to study mechanisms of tumor growth, progression, metastasis, and drug response (Clarke, 1996; Kerbel, 2003; Cespedes et al., 2006) . A caveat in the use of cell lines, however, is their prolonged adaptation to tissue culture conditions that has led to genetic and epigenetic alterations over time (Neve et al., 2006; Kao et al., 2009; Tsuji et al., 2010) . It is also necessary to grow xenografts in immune-compromised mice in vivo where the tumor environment is different from that of native tumors (Clarke, 1996; Kerbel, 2003; Cespedes et al., 2006) .
Genetically engineered mouse models, on the other hand, allow the study of tumor development and progression in immune-competent mice (Borowsky, 2011; Caligiuri et al., 2012) . However, most mouse genetic models rely on the expression of a single, potent oncogene to drive the tumor, and frequently do not recapitulate the full phenotypic repertoire of the human tumor or metastatic patterns seen in breast cancer patients. A review of various cancer models and their utility for drug development can be found in UNIT 14.22 , and also as a summary in Table 14 .23.1.
We have recently reported that directly implanting breast tumor tissues derived from patients into mouse mammary fat pads results in a remarkable recapitulation of human breast cancer. These "tumorgrafts" closely resemble the original tumors from the patient by: (i) maintaining their clinical markers and histopathologies; (ii) maintaining hormone dependence or independence; (iii) maintaining their gene expression and DNA copy number variations; and (iv) recapitulating clinically relevant metastasis (DeRose et al., 2011 and Fig. 14.23.1) . Although the techniques to generate these tumorgrafts can be challenging, the effort is worthwhile as they are the best currently available model of human breast cancer. Such a resource is likely to become a valuable asset for drug discovery efforts, particularly for preclinical animal studies to assess the effectiveness of lead compounds on specific cancer subtypes. In this way, tumorgrafts could help distinguish cancer subtypes that are either responsive or unresponsive to a compound, Patient-derived tumorgrafts Human tissue; cell of origin and oncogenic drivers directly associated with human disease; can be genetically modified; natural evolution in patients; both chemo-naïve and standard-of-care chemo-resistant tissue; no selective pressure from in vitro culturing; molecular and genetic markers highly representative of primary tumors; potential for personalized medicine Not all subtypes grow well in mice; requires immune-compromised mice; laborious; expensive; establishment of bio-bank requires significant coordination between physicians and departments, quality control of specimen processing, IBC regulatory approval for tissue collection, HIPPA, PHI; intellectual property issues and enable clinical trials to be designed around the most appropriate patient population. While a significant investment must be made to establish a bank of transplantable and subtype-diverse tumorgrafts, better prediction of a drug's effectiveness should lead to more successful clinical trials, which would appreciably outweigh the initial investment. Still, the validity and practicality of primary tumorgrafts remains to be verified in a drug development program.
Tumors removed from patients can be processed in many different ways (Table 14. 23.2). Thus, it is important to identify the most appropriate processing technique for a research purpose. Here, we describe three types of tissue processing: tumor fragments, organoids, and single-cell suspensions. The processing occurs sequentially. Tumors are first removed from patients and manually dissected into tissue fragments that can be used for tissue transplantation. Processing of tumor fragments by mincing and enzymatic digestion with collagenase and hyaluronidase leads to tumor organoids, which can be used for transplantation or 3-D culturing. Finally, tumor organoids can be digested with trypsin/EDTA to generate a single-cell suspension for use in transplantation, cell
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Outlined in the present unit are procedures for processing human breast cancer tissue and implanting it into mice (Basic Protocol 1); processing human body fluid (e.g., pleural effusions) for transplantation or storage (Basic Protocol 2); characterizing single cells isolated from human breast tissue or pleural effusions by cell surface markers (Basic Protocol 3); implanting estrogen pellets subcutaneously into mice (Basic Protocol 4); implanting breast tissue into cleared mammary fat pads (Basic Protocol 5); and, implanting breast cancer cells with Matrigel into cleared mammary fat pads (Basic Protocol 6). Details are also provided for the isolation of tumor cells from tumor grafts using enzymatic digestion (Basic Protocol 7); producing and transducing the cells with lentiviruses (Basic Protocol 8); and growing tumorgraft or primary patient organoids in three-dimensional (3-D) cultures for drug discovery and validation (Basic Protocol 9). Support protocols include describing the isolation and storage of human breast tumor tissue (Support Protocol 1); preparation of estrogen pellets (Support Protocol 2); and preparation of growth factor-reduced Engelbreth-Holm-Swarm (EHS) tumor matrix (Support Protocol 3).
NOTE: All human patient tissue samples must be collected from informed, consenting patients under an approved Institutional Review Board for Human Participants (IRB) protocol. Tissue collection at the Huntsman Cancer Institute is coordinated by the Tissue Resource and Applications Core shared resource facility using protocols described in Support Protocol 1. Specific training is provided to all staff members involved in obtaining patient consent, and in the collection and processing of tissue to ensure the acquisition of high-quality biospecimens and compliance with the Health Insurance Portability and Accountability Act (HIPAA) and the protection of Personal Health Information.
NOTE: All protocols using live animals must first be reviewed and approved by an Institutional Animal Care and Use Committee (IACUC) and must follow officially approved procedures for the care and use of laboratory animals (also see APPENDIX 4).
NOTE: All solutions and equipment that come into contact with cells must be sterile, and proper aseptic technique used for work with cell cultures.
NOTE: All culture incubations should be performed in a humidified 37 • C, 5% CO 2 incubator unless otherwise specified. 
PROCESSING HUMAN BREAST TUMORS AND TUMORGRAFTS INTO FRAGMENTS, ORGANOIDS, AND SINGLE CELLS
It is typically preferable to store primary patient and xenograft tumor tissue as fragments since they have a higher transplantation success rate than either organoids or single-cell suspensions (DeRose et al., 2011, and authors' unpub. observ. (Fisher, , sterile 50-ml conical polypropylene centrifuge tubes (e.g., BD Falcon) 37
• C shaker/incubator Centrifuge 24-well standard tissue culture plates Light microscope Additional reagents and equipment for trypan blue exclusion test of cell viability (Strober, 1997) To process solid tissue into fragments 1a. Place the solid tumor tissue (size can vary) in a 10-cm petri dish, pouring sterile serum-free DMEM medium on the tissue to keep it moist.
2a. Cut the tumor into pieces using a scalpel or razor blade, removing necrotic tissue if present. 2b. Mince the tissue using a criss-cross motion with two disposable scalpels until finely chopped, then transfer the minced tissue to a 50-ml conical centrifuge tube using a cell lifter.
3b. Add digestion reagent(s) (collagenase and/or hyaluronidase solution) to a final volume of 10 ml per g of tissue.
i. 4b. Close the tube with a cap and wrap the cap with Parafilm (Parafilm helps to prevent leakage and potential bacteria/yeast contamination of the area around the cap). Place the tube on its side in a 37 • C shaker at low to moderate speed (e.g., 200 rpm 8b. Resuspend the pellet in 10 ml of DMEM/F12 medium (with no supplements) and centrifuge 10 to 30 sec at 530 × g, room temperature. Collect both the supernatant (suspension fraction) and pellet (organoid fraction). Collect the cells in the suspension fraction by centrifuging 5 min at 530 × g, room temperature, and removing the supernatant. Resuspend each fraction in 1 ml DMEM/F12 medium (with no supplements). Take a 10-to 25-μl sample of the resuspended fraction and dilute 1:10 to 1:100 in DPBS. Place 25 μl of each dilution in an empty well of a 24-well standard tissue culture dish. Examine the quality of the fraction under a light microscope. 9b. Resuspend the pellet from the organoid fraction in 9 ml of DMEM/F12 medium (with no supplements) and centrifuge 10 to 30 sec at 530 × g, room temperature, to pellet the cells. Centrifuge the suspension fraction 5 min at 530 × g, room temperature, to pellet the suspended cells. Analyze both samples as described in step 8b. To further enrich organoids from single cells, perform differential centrifugation by repeating this step three to four times until the desired level of organoid enrichment is achieved. 10b. Estimate the number of organoids in the final sample and calculate the approximate total number of organoids recovered from the tissue. Culture the 24-well plate containing the 25-μl samples used to assess the fractionation procedure (step 8b) overnight in 0.5 ml/well of HBEC medium to determine whether the sample is contaminated with bacteria or fungus. 11b. Proceed to cryopreservation (step 12b), transplantation (Basic Protocol 6), single cell processing ("c" steps, below), or 3-D cell culture (Basic Protocol 9), if applicable. 6c. Aspirate the supernatant and carefully resuspend the pellet with 5 ml of HBSS containing 2% FBS by pipetting up and down. Perform a trypan blue exclusion test using a hemacytometer to determine the number of viable cells per ml (Strober, 1997) .
7c. For cryopreservation, resuspend the pellet in HBEC freezing medium (do not confuse with tissue freezing medium) at a concentration of ∼5-10 × 10 6 cells per ml and freeze in 1-ml aliquots as described above. 
PROCESSING HUMAN BODY FLUID (e.g., PLEURAL EFFUSION, ASCITES)
In addition to solid tumors, patients with metastatic breast cancer can present with a pleural effusion, which is a buildup of fluid and tumor cells in the pleural cavity. It is not unusual for 500 ml to 1.5 liters of effusion fluid to be collected from a single patient, which can contain large amounts of tumor cells. This fluid can be a very rich source of metastatic breast cancer cells, but can contain other contaminating cell types, such as lymphocytes, macrophages, and fibroblasts. Therefore, cells isolated from pleural effusions or ascites fluid should be characterized by cell surface markers, as described in Basic Protocol 3.
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Materials
Fresh human effusion samples (handle under BSL-2 conditions) TAC solution (see recipe) Hyclone Hanks' balanced salt solution (HBSS; Thermo Scientific, cat. no. SH30268.02) Dulbecco's phosphate-buffered saline (DPBS; Invitrogen, cat. no. 14040-141) HBEC freezing medium (see recipe) 50-ml conical tubes, sterile 500-ml centrifuge bottles (Nalgene, cat. no. 3122-0500) Light microscope 1-to 1.5-ml cryovials, sterile Additional reagents and equipment for freezing cells (Basic Protocol 1) 1. Transfer the freshly acquired effusion fluid to a 50-ml conical tube on ice. For largevolume samples, use sterile 500-ml Nalgene centrifuge bottles.
2. Centrifuge the fluid for 5 min at 530 × g, 4 • C, and collect the pellet. 3. If the pellet contains red blood cells (observed in the top layer of the cell pellet), resuspend the pellet in 5 to 10 ml of TAC solution and incubate the sample for 3 to 10 min in a 37 • C water bath. Centrifuge 5 min at 530 × g, room temperature. Repeat this step until the blood cells are no longer visible.
4. Resuspend the pellet in 5 to 10 ml of HBSS or DPBS.
5. Centrifuge 5 min at 530 × g, room temperature.
6. Resuspend the pellet in 5 to 10 ml HBSS or DPBS and assess its content by plating 25 μl into a dish and examining the cellular organization under a light microscope (organoids and single cells; 9. For cryopreservation, resuspend the pellet in HBEC freezing medium (do not confuse with tissue freezing medium) to a concentration of approximately 1,000,000 organoids or 5 to 10 million cells per ml and freeze in 1-ml aliquots as described in Basic Protocol 1.
BASIC PROTOCOL 3
CHARACTERIZATION OF SINGLE CELLS ISOLATED FROM HUMAN TUMORS, BODY FLUID, OR FROM TUMOR GRAFT TISSUE USING FLUORESCENCE ACTIVATED CELL SORTING (FACS)
Primary human tumors typically contain heterogeneous cell populations, including stromal and immune cells, in addition to tumor cells with diverse tumorigenic capacity. It has been shown that these different populations can be characterized using cell-surface markers such as epithelial cell adhesion molecule (EPCAM) and CD49f (α6 integrin), which can differentiate luminal (EPCAM Hi /CD49f Low ) versus basal/myoepithelial cells (EPCAM low /CD49f Hi ) in normal breast tissue, and exhibit distinct expression in breast cancer subtypes (Keller et al., 2010) . In addition, the cell-surface markers CD44 Hi and CD24 Low have been used to identify a population of breast cancer cells with enhanced tumor-initiating capabilities in mouse transplantation assays (Al-Hajj et al., 2003) . Since every patient sample may contain different populations of tumor cells as well as contaminating nonepithelial cells, such as lymphocytes, macrophages, and fibroblasts, it is important to characterize single cells isolated from human breast tumors (Basic Protocol 1), human body fluids (Basic Protocol 2), or tumorgraft tissue (Basic Protocol 8).
The protocol involves staining single-cell suspensions derived from tumors with a variety of antibodies that differentially mark specific cell populations. For example, 7-AAD is used to exclude dead cells, and a cocktail of antibodies (CD2, CD3, CD10, CD16, CD18, CD31, CD64, and CD140b) is used to exclude nonepithelial cells (lineage positive), such as lymphocytes, macrophages, and fibroblasts. Simultaneously, the cells are stained with combinations of antibodies that recognize tumor markers, such as EPCAM, CD49f, CD44, and CD24, which are expressed on diverse tumor cell populations. The cell suspension is then analyzed or sorted into enriched cell fractions by flow cytometry. An example of a typical FACS analysis of primary cells isolated from pleural effusions from two patients is illustrated in Figure 14 .23.4A and B. Additionally, the percentage of lineage-positive (nonepithelial) and CD44 Hi /CD24 Low (tumor-initiating) cells from seven different primary patients' samples is presented in Figure 14 .23.4C. These data demonstrate that every patient sample contains different percentages of lineage-positive and CD44 Hi /CD24 Low populations. Typically, we do not utilize primary patient cells that contain high levels (>30% to 40%) of lineage-positive cells for the three-dimensional primary tumor cultures described in Basic Protocol 9.
Materials
Solid tumor or body fluids Modified M87 medium (see recipe) Dulbecco's phosphate-buffered saline (DPBS; Invitrogen, cat. no. 14040-141) 0.05% trypsin-EDTA (Invitrogen, cat. no. 25300-054) Hyclone Hanks' balanced salt solution (HBSS; Thermo Scientific, cat. no. SH30268.02) Characterized fetal bovine serum (FBS), heat-inactivated (Thermo Scientific, cat.
no. SH30071.03) All of the reagents/antibodies listed in Table 14.23.3 Swinging-bucket centrifuge 15-and 50-ml conical centrifuge tubes (e.g., BD Falcon) 10-cm tissue culture treated polystyrene cell culture dish (BD Falcon, cat. no.
353003) 100-μm cell strainer (BD Falcon, cat. no. 352360) 12 × 75-mm round-bottom polystyrene FACS tube (BD Falcon, cat. no. 352008) 4-color FACS machine capable of detecting FITC, PE, 7-AAD, and APC fluorochromes (also see Coligan et al., 2012, Chapter 5) Additional reagents and equipment for trypan blue exclusion test of cell viability (Strober, 1997) and flow cytometry (Coligan et al., 2012, Chapter 5) Culture freshly prepared tumor cells overnight The cells are cultured overnight in order to allow them to recover from the tissue processing procedure (Basic Protocols 1 and 8) before performing FACS staining. Alternatively, cells can be used directly after processing, but they may be more susceptible to dying during the staining procedure 1a. For freshly isolated tumor cells: Prepare fresh single tumor cells from solid tumor or body fluids as described in Basic Protocol 1 or 2, then continue this protocol at step 5.
1b. For cryopreserved cells: Defrost a vial of cryopreserved human primary tumor cells by submerging it in a 37 • C water bath for 2 to 3 min. As soon as the vial is thawed, transfer the contents to a 15-ml conical tube containing 10 ml of modified M87 medium that has been prewarmed to 37 • C.
2. Centrifuge the cells for 5 min at 400 × g, room temperature.
3. Aspirate the supernatant and carefully resuspend the pellet into 1 ml of modified M87 medium that has been prewarmed to 37 • C by pipetting up and down.
4. Perform a trypan blue exclusion test using a hemacytometer to determine the number of viable cells per ml (Strober, 1997) .
5. Adjust the concentration of cells to 4-6 × 10 6 cells in 10 ml by addition of modified M87 medium that has been prewarmed to 37 • C.
6. Add 10 ml of the cell suspension to a 10-cm tissue culture-treated dish. Incubate the cells at 37 • C in a 5% CO 2 humidified incubator, overnight.
Collect cells after overnight incubation
7. Remove the plate from the incubator and collect the medium, which may contain nonadherent tumor cells, and transfer to a 50-ml conical tube on ice.
Some pleural effusions contain nonadherent tumor cells that do not need to be trypsinized prior to FACS. However, if the nonadherent tumor cells are aggregated in clusters or organoids, they should be processed into single cells as described in Basic Protocol 1, steps 1c to 8c. The presence or absence of adherent cells does not necessarily correlate with the percentage of lineage positive (nonepithelial) cells.
8. To remove adherent cells, immediately wash the plate with 10 ml of DPBS and transfer the solution to the 50-ml conical tube containing the cell suspension on ice. Add 1 ml of 0.05% trypsin-EDTA to the plate.
9. Incubate the cells with trypsin for 1 to 5 min at 37 • C until the adherent cells detach. Gently pipet up and down to mix the trypsin solution and transfer it to the 50-ml conical tube containing the suspension cells.
10. Wash the plate with 10 ml of HBSS containing 2% FBS and transfer the solution to the 50-ml conical tube containing the cell suspension on ice.
11. Centrifuge the cells for 5 min at 400 × g at 4 • C.
12. Aspirate the supernatant and carefully resuspend the pellet with 5 ml of HBSS containing 2% FBS by pipetting up and down. Perform a trypan blue exclusion test using a hemacytometer to determine the number of viable cells per ml (Strober, 1997) .
13. Adjust the concentration to 1.0 × 10 6 cells/ml by adding HBSS containing 2% FBS on ice and proceed to the staining, step 14. Prepare cells for FACS analysis of CD44/CD24 and EPCAM/CD49f markers 14. Add 1 ml of the single-cell suspension at 1.0 × 10 6 cells/ml to nine 15-ml conical tubes (1.0 × 10 6 cells/sample) for each staining condition listed below. FACS analysis and gating procedure 25. Analyze tubes a to e, g, and h by flow cytometry (Coligan et al., 2012, Chapter 5) to set up the gates, detector voltages, and compensation.
26. Analyze samples f and i and use the sequential gates described below. Examples of the FACS plots and gating procedure are illustrated in Figure 14 .23.4A and B. and place it in a prone position. Stabilize the mouse by gently fixing its legs to the platform with tape, making sure that the nose cone is secured for continuous delivery of vaporized isoflurane. Remove the fur from the surgical area between the shoulder blades (approximately 6 × 6-mm) by applying a depilatory cream and gently removing the hair with a cotton swab.
3. Pinch the footpad to make certain the mouse is in the proper plane of anesthesia before surgery. If the animal responds to the pinch by twitching, allow more time for the anesthesia to take effect.
4. When the mouse is fully anesthetized, disinfect the skin with 70% ethanol and wipe three times with betadine using a swab stick.
5. Make a small (3-mm) incision between the shoulder blades (see Fig. 14 .23.5), being careful not to cut any muscle. Make a subcutaneous pocket for the estrogen pellet using blunt dissection technique. Apply lidocaine-bupivacaine mixture to the exposed tissue.
6. Insert one pellet into the pocket.
7. Close the incision with a wound clip.
Proceed to breast tumor transplantation (Basic Protocol 5).
BASIC PROTOCOL 5
IMPLANTATION OF BREAST TUMOR TISSUE FRAGMENTS INTO MICE
This is a subcutaneous procedure that does not require laparotomy. We perform this procedure on mice that are 3 to 4 weeks of age to facilitate simultaneous clearing of the immature endogenous mouse mammary tissue (a video demonstrating clearance of mouse mammary fat pads for tissue transplantation can be found at: http: //www.jove.com/ video/1849/mammary-epithelial-transplant-procedure mammary tissue at 3 to 4 weeks, followed by a second surgery to implant tumor cells at a later date. All tumors are implanted into the inguinal (4th) mammary fat pad (Hummel et al., 1966, and Fig. 14.23.5) . We occasionally implant tumors into both contralateral fat pads if the goal is to amplify tumor tissue. We use the same procedure for NOD/SCID (The Jackson Laboratory, stock #1303) and NOD/SCID/IL2Rγ -/-(NSG) mice (The Jackson Laboratory, stock #5557). Surgery should not be performed on the same day the mice are transported from another facility. If mice are shipped from a vendor, we allow them to acclimatize for 4 to 7 days prior to surgery.
Materials
Tumor samples for implantation fresh or frozen (see Basic Protocols 1 and 2) NOD/SCID mice (The Jackson Laboratory, stock #1303); alternatively, the more immune-compromised NOD/SCID/IL2Rγ -/-(NSG) mice ( 1a. For fresh tissue: Prepare 4 × 2-mm tumor tissue fragments as described in Basic Protocol 1. Place fresh tissue fragments in a 1.5-ml sample tube with ∼ 0.5 ml sterile HBEC medium (alternatively, DPBS, DMEM/F12, or RPMI can be used) to keep the tissue moist. Place the tube on ice until implantation.
1b. For cryopreserved tissue: Thaw frozen tissue fragments by placing the vial in a 37 • C water bath and removing before the medium completely melts. Spray the outside of the vial with 70% ethanol, then move the vial into a biosafety hood and place the contents in a 50-ml conical tube. Add 10 ml of HBEC medium, then aspirate to remove the DMSO-containing freezing medium. Repeat three times. Add fresh HBEC medium, close the lid, and place the tube on ice until the implantation.
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Supplement 60 Current Protocols in Pharmacology 2. Set up the surgical suite. Turn on the heating pad and set the water temperature to 38 • C. Autoclave surgical tools at the beginning of the procedure and disinfect in between animals using a hot bead sterilizer. Disinfect the surgical bench area by wiping with a disinfectant such as Clidox−S.
3. Anesthetize the mouse by exposure to 2% to 2.5% vaporized isoflurane in oxygen using an induction chamber, then transfer it to the surgical platform and place it in a supine position. Stabilize the mouse by gently fixing its legs to the platform with tape, making sure the nose cone is in place for continuous delivery of vaporized isoflurane. Denude the surgical area by applying a depilatory cream and gently removing the hair with a cotton swab.
4. Pinch the footpad to make certain the mouse is in the proper plane of anesthesia. If the animal responds to the pinch by twitching, allow more time for the anesthesia to take effect. When the mouse is fully anesthetized, disinfect the skin with 70% ethanol and wipe three times with betadine using a swab stick.
5. Make two small subcutaneous incisions in the skin to expose the fat pad: one along the midline (approximately 1.5 cm) and one a short distance down the leg (about 1.2 cm; Fig. 14.23 .5). Apply lidocaine/bupivicaine anesthetic mixture to the incision using a swab stick. 6. Expose the mammary fat pad using a sterile cotton swab, and pin the skin down using a small needle. Locate the inguinal lymph node in the middle of the fat pad (it is paler than the surrounding fat pad, has a kidney bean shape and is located at the junction of blood vessels).
Using the lymph node as a reference for the center of the gland, the site of transplantation is in the center of the half of the fat pad that is proximal to the peritoneum (see Fig. 14.23.5). 7. Insert the tip of a cross-action tweezers into the center of the transplantation site and make a pocket about 3 mm long. Place a tumor fragment into the pocket. Carefully remove the tweezers once the tissue has been placed.
8. Clear the mammary fat pad by using forceps and scissors. Grasp the portion of fat pad closest to the nipple and cut under the fat pad with the scissors, keeping the scissors parallel and adjacent to the skin. Continue cutting the fat pad along the skin until the lymph node is reached. Cut across the width of the fat pad immediately adjacent (on the peritoneal side) to the lymph node, and remove this fat pad tissue to clear the gland. Be careful not to disrupt the pocket containing the tumor fragment. 9. Close the incision with wound clips. Place the mouse on the warm pad until it awakens. Return the mouse to its home cage.
10. Monitor the mice according to the approved IACUC protocol-we monitor the mice daily for 3 to 5 days post-surgery and remove wound clips within 7 to 10 days. Check tumor growth weekly and determine and record its size with the caliper. 
TRANSPLANTING TUMOR CELLS AND ORGANOIDS INTO MICE
Organoids and cells isolated from digestion of solid tissue, or separated from body fluid (using procedures described in Basic Protocols 1 and 2), can be injected into cleared mouse fat pads to generate tumor grafts. We typically inject cells and organoids with Matrigel to facilitate their growth. 2. Inject the cell/Matrigel mixture into mammary fat pads using a similar procedure to that described in Basic Protocol 5, with the exception that a tissue pocket is not used. Instead, inject 20 μl Matrigel/cell mixture directly into the mammary fat pad using an insulin syringe with a 27-G × 1 / 2 in. needle. Plastic petri dish (Fisher Scientific, 15-and 50-ml conical tubes, sterile 1-to 1.5-ml cryovials, sterile Hyclone DMEM/F12 (1:1) with HEPES (Thermo Scientific, cat. no. SH30023.01)
Materials
Additional reagents and equipment for CO 2 asphyxiation of the mouse (Donovan and Brown, 2006) and freezing of samples (Basic Protocol 1, "b" steps)
1. Clean the workbench and all equipment with 70% ethanol.
2. Euthanize the mouse by CO 2 asphyxiation following IACUC-approved procedures (Donovan and Brown, 2006) .
3. Lay the mouse in a supine position on the surgical platform and clean the incision area with 70% ethanol.
4. Make an incision to expose the tumor. Carefully detach the skin from the tumor using cotton swabs and scissors.
5. Measure the tumor (length × width × height) and record (it is easier to measure the tumor before isolating it from the skin). Carefully remove the tumor.
6. Record the wet weight of the tumor. 9. For histological analysis: Fix tissue samples in 2 to 5 ml of cold 4% PFA in a 15-ml conical tube. Keep the sample tubes on ice until they are ready to be stored in the refrigerator (fixation is typically overnight at 4 • C). Move the samples to 70% ethanol and store at 4 • C no longer than 1 week prior to embedding in paraffin. Section and stain the tissue as desired.
For nucleic acid and protein isolation:
Place the samples in a cryovial or wrap in aluminum foil and submerse in liquid nitrogen to flash freeze. Transfer the tissue to a −80 • C freezer. Isolate nucleic acids or protein using any of several standard methods.
For transplantation:
Cut the tumor tissue into approximately 4 × 2-mm fragments and freeze in tissue freezing medium (do not confuse with HBEC freezing medium) in cryovials. Freeze at −80 • C overnight as described in Basic Protocol 1, "b" steps, and then store in liquid nitrogen. Transplant the tissue as described in Basic Protocol 5.
For processing into viable cells:
Place the solid tumor tissue (size can vary) in a 50-ml conical tube containing sterile DMEM/F12 medium. Keep the tissue on ice until processing can be performed as described in Basic Protocol 1.
BASIC PROTOCOL 8
PRODUCING AND UTILIZATION OF LENTIVIRUSES FOR TRANSDUCTION OF TUMOR CELLS
Bioluminescence and/or fluorescence imaging techniques are useful for monitoring tumor growth in live animals and to locate metastases. However, tumor cells derived from patients and tumorgrafts can have low transfection or transduction rates when standard procedures are employed. Therefore, concentrated lentiviruses are utilized, since they are able to effectively transduce primary cells. This protocol describes the production and titering of a concentrated lentivirus, which co-expresses both ZsGreen and luciferase (pHIV-Luc-ZsGreen), for the purpose of labeling cells to identify micrometastases in tumorgrafts. In addition, a suspension infection method adapted from Welm et al. (2008) , which is used to transduce primary cells, including mixed adherent/suspension cultures, is described below.
Materials
HEK 293T cells (ATCC #CRL-11268)
DMEM medium with high glucose and L-glutamine (Invitrogen, cat. no. 11965-092) Characterized, heat-inactivated fetal bovine serum (FBS) (Thermo Scientific, cat.
no. SH30071.03) Dulbecco's phosphate-buffered saline (DPBS; Invitrogen, cat. no. 14040-141) 0.05% trypsin-EDTA (Invitrogen, cat. no. 25300-054) Polyethylenimine (PEI), branched, average mol. wt. ∼25,000 by LS (Sigma, cat. no. 408727-100 ml) OPTI-MEM reduced serum medium with L-glutamine (Invitrogen, cat. no. 31985-070) 0.5 to 1 μg/μl pHIV-Luc-ZsGreen (Addgene, cat. no. 39196) 0.5 to 1 μg/μl solution of pMDLg/pRRE 3rd-generation packaging plasmid (Addgene, cat. no. 12251) 0.5 to 1 μg/μl solution of pRSV-Rev 3rd-generation packaging plasmid (Addgene, cat. no. 12253) 0.5 to 1 μg/μl solution of pCMV-VSV-G envelope plasmid (Addgene, cat Additional reagents and equipment for counting cells using a hemacytometer (Strober, 1997) , flow cytometry (Coligan et al., 2012, Chapter 5) , and preparation of organoids (Basic Protocol 1)
Prepare concentrated lentiviral particles NOTE: All protocols using lentiviruses must be reviewed and approved by an Institutional Biosafety Committee. BSL2 techniques are employed when generating and utilizing lentiviruses.
1. Expand HEK 293T cells in DMEM medium supplemented with 10% FBS (heat inactivated) in 10-cm tissue culture dishes. Culture the cells at 37 • C in a 5% CO 2 humidified incubator.
For unknown reasons, high-passage HEK 293T cells do not produce high-titer lentivirus. It is best to obtain a fresh stock of HEK 293T from the ATCC (#CRL-11268) rather than acquire stocks from other laboratories. Also, cryopreserve early-passage cells and thaw a fresh stock for the generation of high-titer lentivirus.
2. Aspirate the medium and wash each plate with 5 ml of DPBS.
3. Add 1 ml/plate of 0.05% trypsin-EDTA and incubate for 2 to 5 min. Gently pipet up and down to mix the trypsin solution.
4. Add 10 ml/plate of DMEM medium supplemented with 10% FBS (heat-inactivated) and determine the number of cells per ml using a hemacytometer (Strober, 1997) .
5. Plate 4-7 × 10 6 cells into each 10-cm tissue culture dish and adjust the volume of each plate to 10 ml with DMEM medium supplemented with 10% FBS (heat inactivated). Culture the cells overnight at 37 • C in a 5% CO 2 humidified incubator. 6. Aspirate the medium, add 8 ml/plate of DMEM medium supplemented with 10% FBS (heat inactivated) that has been prewarmed to 37 • C, and culture for 2 hr.
7. Prepare PEI at 1 mg/ml (w/v) in deionized sterile water.
The transfection procedure described in this protocol is optimized for PEI (Huh et al., 2007 at −20 • C for up to 1 year. If a different transfection reagent will be used, optimization will be necessary.
8. Add 720 μl of the 1 mg/ml PEI solution to 11.28 ml of OPTI-MEM medium in a 50-ml conical tube, which yields a solution sufficient to transfect 24 plates (30 μg of PEI per plate in 500 μl of OPTI-MEM).
The volume can be adjusted depending on the number of plates utilized.
9. Prepare a solution of plasmids in a separate 15-ml conical tube, which is enough to transfect 24 plates, by adding 120 μg of pHIV-Luc-ZsGreen (5 μg/plate), 40.8 μg of pMDLg/pRRE (1.7 μg/plate), 40.8 μg of pRSV-Rev (1.7 μg/plate), and 40.8 μg of pCMV-VSV-G (1.7 μg/plate) to a final volume of 12 ml of OPTI-MEM medium (500 μl/plate). 10. Add 12 ml of the plasmids/OPTI-MEM solution (prepared in step 9) to the 12 ml of PEI/OPTI-MEM (prepared in step 8) and mix. Incubate the solution for 30 min at room temperature.
It is important to utilize plasmid solutions at
11. Add 1 ml/plate dropwise of the PEI/plasmid/OPTI-MEM solution from step 10 to the plates from step 6, gently swirl the plates, and culture cells with solution for 24 hr at 37 • C in a 5% CO 2 humidified incubator.
12. From this point forward, utilize BSL2 procedures according to your institution's biosafety protocol. Every time before working with solutions containing virus, place a large beaker containing >50 ml of bleach in a biosafety cabinet to disinfect any medium and pipets (make sure the final concentration of bleach is >10% before removing it from the biosaftey cabinet). 13. Remove the medium from each plate and transfer it to the beaker containing bleach. Add 8 ml/plate of DMEM medium containing 10% FBS (heat inactivated) that has been pre-warmed to 37 • C and incubate overnight at 37 • C in a 5% CO 2 humidified incubator.
14. The following day (48 hr post transfection), remove the medium from each plate and transfer it to a 50-ml conical tube on ice. Immediately add 8 ml/plate of fresh prewarmed DMEM medium containing 10% FBS (heat inactivated) to each plate and culture overnight at 37 • C in a 5% CO 2 humidified incubator. 15. Centrifuge the 50-ml conical tubes containing the medium for 10 min at 2500 × g at 4 • C to pellet any large debris. 
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17. To pellet the virus, ultracentrifuge the solution for 1 hr 45 min at 112,000 × g, 4 • C, using an SW28 swinging-bucket rotor.
18. Carefully remove the supernatant and transfer it to a beaker containing bleach. Immediately (do not let the pellet dry) add 150 μl of DMEM/F12 medium to each centrifuge tube on ice. Gently pipet up and down without creating bubbles to dissolve the pellet. Place the ultracentrifuge tubes in a 50-ml conical tube and cap the conical tube to prevent evaporation of the solution. Store the conical tubes at 4 • C overnight.
19. The following day, collect the second round of medium from the plates (72 hr post transfection) and process it in the same manner as in steps 14 to 17.
Add bleach at a final concentration of 10% to the plates, incubate at room temperature for 20 min in the biosafety cabinet, and discard plates and medium.
20. After the ultracentrifugation in step 17, remove the supernatant. Resuspend the pellets by transferring the DMEM/F12 solution containing the concentrated virus that was collected 48 hr post transfection to each tube. Gently pipet up and down to dissolve the pellet. Place the ultracentrifuge tubes in a 50-ml conical tube to prevent evaporation, and incubate at 4 • C for 2 hr to ensure the virus is completely dissolved.
21. Pipet up and down to resuspend the pellets, being careful to limit bubbles. Combine all of the resuspended pellets into one tube and gently pipet to mix. Aliquot 50 to 100 μl of the concentrated virus into 500-μl microcentrifuge tubes and store at −80 • C.
The virus solutions are aliquotted to minimize freeze/thaws, which can significantly reduce the number of IU/ml. The virus solutions can be stored up to 1 year at −80
• C.
Determine infectious units (IU)/ml by FACS
22. Expand HEK 293T cells in DMEM medium supplemented with 10% FBS (heatinactivated) in 10-cm tissue culture dishes. Culture the cells at 37 • C in a 5% CO 2 humidified incubator.
23. Aspirate the medium and wash each plate with 5 ml of DPBS.
24. Add 1 ml/plate of 0.05% trypsin-EDTA and incubate for 2 to 5 min at 37 • C in a 5% CO 2 humidified incubator. Gently pipet up and down to mix the trypsin solution.
25. Add 10 ml/plate of DMEM medium supplemented with 10% FBS (heat inactivated) and determine the number of cells per ml using a hemacytometer (Strober, 1997) .
26. Plate 2.0 × 10 5 cells in each well of a tissue-culture-treated 6-well tissue culture plate and adjust the volume to 3 ml/well with DMEM medium supplemented with 10% FBS (heat inactivated). Culture the cells overnight at 37 • C in a 5% CO 2 humidified incubator.
27. Aspirate the medium from four wells of the 6-well plate and add 1 ml/well of DMEM medium supplemented with 10% FBS (heat inactivated) that has been prewarmed to 37 • C.
28. Aspirate the medium from the remaining two wells of the 6-well plate and carefully wash with 2 ml/well of DPBS so the cells do not detach.
29. Add 0.5 ml of 0.05% trypsin-EDTA to each of the two wells and incubate for 2 to 5 min at 37 • C in a 5% CO 2 humidified incubator. Gently pipet up and down to mix the trypsin solution. 30. Add 0.5 ml/well of DMEM medium supplemented with 10% FBS and determine the number of cells present in each well independently using a hemacytometer (Strober, 1997) . Calculate the average number of cells present in each of the two wells. 34. Remove the medium 24 hr post infection and put into bleach. Add 3 ml/well of DMEM medium supplemented with 10% FBS (prewarmed to 37 • C) and culture for 2 additional days.
35. Remove the medium 72 hr post infection and put into bleach. Carefully wash the wells with 2 ml/well of DPBS so the cells do not detach.
36. Add 0.5 ml/well of 0.05% trypsin-EDTA and incubate for 2 to 5 min. Gently pipet up and down to mix the trypsin solution.
37. Transfer the cell suspension to a 15-ml conical tube on ice. Wash each well with 1 ml of HBSS containing 2% FBS and transfer this solution to the respective 15-ml conical tube.
38. Add paraformaldehyde to a final concentration of 2% to each tube and incubate at 4 • C for 20 min to inactivate any residual virus that may be present. 43. Pass the cell suspension through a 100-μm cell strainer and transfer to a FACS tube.
44. Set up the gates and detector voltages, and analyze samples by flow cytometry using the sequential gates described below (Coligan et al., 2012, Chapter 5 48. Trypsinize the tissue at room temperature, and carefully monitor the organoid dissociation process every few minutes under low magnification using a light microscope. Trypsinize for 1 min, then very gently pipet the cells up and down with a 1-ml pipet to help dissociate the organoids into single cells. Repeat every minute until most of the organoids are dissociated.
49. Once the organoids are dissociated, immediately add 5 ml HBEC medium (or DMEM/F12 containing 10% FBS) to neutralize the trypsin, and centrifuge the cells 5 min at 530 × g, room temperature. Wash cells with 5 ml medium two additional times.
Resuspend the pellet in HBEC medium and count the cells using a hemacytometer (Strober, 1997) . 51. Add polybrene to a final concentration of 1 to 4 μg/ml (the actual concentration should be empirically determined using the target cells). Add concentrated lentivirus using a multiplicity of infection (MOI) of 5 to 20 viral particles/target cell. Add additional HBEC medium to bring the final volume to 1 ml per well.
If the pellet is difficult to resuspend because of viscosity, it is likely due to the presence of DNA from cells that lysed. In this case, incubate the cells with 10 μg/ml
The MOI may also have to be optimized for different tumors.
52. Centrifuge the plate 1 hr at 700 × g, room temperature. Alternatively, proceed directly to step 54 without performing the centrifugation, replacing the virus-containing medium with fresh HBEC medium after overnight incubation.
Some cells are more efficiently infected using a combination of the spin method and overnight suspension culturing with virus. This can only be determined empirically.
53. Remove the virus medium and add 2 ml of fresh HBEC medium.
54. Incubate at 37 • C in 5% CO 2 humidified incubator-expression of virus proteins (e.g., ZsGreen) should be detectable by fluorescence microscopy after 72 hr. Feed the cells every day by exchanging the medium.
55. Expand the cells until a sufficient number is obtained to transplant the desired number of mouse mammary fat pads (see Basic Protocol 6). 
THREE-DIMENSIONAL PRIMARY TUMOR CULTURES
The physical organization of breast cancer in three dimensions (3-D) modulates signaling pathways that affect the survival, growth, and sensitivity of tumor cells to therapeutics. Primary tumor organoids can be grown in 3-D culture to study the complex cell-cell and cell-matrix interactions that occur in vivo. Every primary human or xenograft tumor may require different medium supplements for optimal growth. A standardized medium is typically used to simplify in vitro culturing conditions. The medium that we use is a modified version of the M87 medium developed by the Stampfer laboratory that supports the growth of human primary mammary epithelial cells (Garbe et al., 2009 ). We have cultured several primary and xenograft tumor cells successfully for up to 2 weeks using this medium, although additional optimization may be possible.
Materials
Vial of cryopreserved human primary tumor cells Modified M87 medium (see recipe) Organoids, dissociated tumor cells, or pleural effusion cells (see Basic Protocols 1 and 2) Growth factor-reduced Matrigel (see recipe) Test compounds Vehicle (e.g., DMSO) Cell Titer 96 aqueous non-radioactive cell proliferation assay (MTS Assay) (Promega, cat. no. G5421) Live/dead viability/cytotoxicity kit for mammalian cells (Invitrogen, 15-and 50-ml conical tubes, sterile (e.g., BD Falcon) 24-well ultra-low-cluster (adhesion) flat-bottom plates (Corning Costar, cat. no. 3473) Centrifuge Light microscope 55-ml disposable reagent reservoir (Bioexpress, cat. no. B-0812-7) 96-well untreated clear U-bottom plates (BD Falcon, cat. no. 351177) 12-channel pipettor 50-ml multichannel pipetting reservoir 96-well clear flat-bottom plates (BD Falcon, cat. no. 353915) 96-well black Cell Star clear flat-bottom plate (Greiner Bio-One, cat. no. 655090) Plate reader capable of reading absorbance at 490 nm Confocal microscope Additional reagents and equipment for counting cells using a hemacytometer (Strober, 1997) Models of Human Breast Cancer
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Defrost cryopreserved tumor cells (if applicable) 1. Defrost a vial of cryopreserved human primary tumor cells by submerging it in a 37 • C water bath for 2 to 3 min. As soon as the vial is thawed, transfer the contents to a 15-ml conical tube containing 10 ml of modified M87 medium that has been prewarmed to 37 • C.
2. Centrifuge the cells for 5 min at 700 × g, room temperature.
3. Aspirate the supernatant and carefully resuspend the pellet into 1 ml of modified M87 medium by pipetting up and down. Perform a trypan blue exclusion test using a hemacytometer to determine the number of viable cells per ml (Strober, 1997) .
Aggregate single tumor cells (if applicable)
Typically, organoids are used for the 3-D in vitro assay. Organoids prepared as described in Basic Protocol 1 can be embedded directly in Matrigel. Dissociated tumor cells and pleural effusion cells (Basic Protocol 2) should be aggregated prior to embedding in Matrigel. However, some pleural effusion cells do not aggregate under these conditions.
4. Suspend the single cells in modified M87 medium to achieve a concentration of 1-4 × 10 6 cells/ml.
5. Add 1 ml of tumor cell suspension to each well of a 24-well ultra low-adhesion plate.
Incubate the cells at 37 • C in a 5% CO 2 humidified incubator overnight.
6. Separate tumor aggregates from single cells by differential centrifugation. Place aggregates in a 15-ml conical tube with 5 ml of modified M87 medium and centrifuge for 30 sec to 1 min at 450 × g, room temperature (single cells will remain in suspension while cellular aggregates pellet). Remove the supernatant and resuspend the pellet in 5 ml of modified M87 medium. Monitor the organoid enrichment procedure by analyzing 25-μl samples of the resuspended pellet by light microscopy. Repeat centrifugation process two to five times as needed to enrich for aggregated tumor cells.
Embed tumor organoids or aggregates in Matrigel 7. Defrost a bottle or aliquot of frozen growth factor-reduced Matrigel at 4 • C.
This process can take several hours to overnight. It is very important to keep the Matrigel at 4
• C at all times to prevent it from solidifying.
8. Carefully transfer the organoids/aggregates to a 15-ml conical tube containing 10 ml of the modified M87 medium that has been prewarmed to 37 • C. Centrifuge the cells for 30 sec at 400 × g at room temperature. Aspirate the supernatant to remove the single cells. Resuspend the pellet by slowly adding 1 ml of modified M87 medium, taking care to avoid breaking up the organoids. Perform a trypan blue exclusion test using a hemacytometer to determine the number of viable organoids/aggregates per ml (Strober, 1997) .
9. Centrifuge the organoids/aggregates 5 min at 400 × g, room temperature. Remove the supernatant and place the tube on ice. Determine the number of organoids and the volume of Matrigel to be added to each well of a 96-well plate. 10. Based upon the experiment (MTS or Live/Dead), determine the total number of wells and amount of Matrigel required to achieve the proper concentration of organoids/aggregates per ml. Carefully suspend the pellet of organoids/aggregates in Matrigel on ice.
11. Transfer the Matrigel cell suspension to a 50-ml disposable reservoir on ice. Using a 12-channel pipettor, carefully mix the suspension by gently pipetting up and down. If performing an MTS endpoint assay, add 30 to 40 μl of the cell suspension/Matrigel mixture to each well of the 96-well plate. If performing a live/dead assay, add 50 to 100 μl of the Matrigel/cell suspension to each well of the 96-well plate.
Care should be taken to avoid the formation of bubbles by pipetting slowly.
12. To reduce the settling of organoids onto the bottom of the plate while the Matrigel solidifies, carefully invert the 96-well plate (surface tension will maintain the Matrigel/cell suspension in the well) and place it in a 37 • C, 5% CO 2 humidified incubator for 30 min.
13. Remove the plate from the incubator and add 75 to 100 μl of modified M87 medium to each well with a 12-channel pipettor. Incubate the cells overnight at 37 • C in a 5% CO 2 humidified incubator.
Treat 3-dimensional cultures with test compounds
Primary human tumor cells typically proliferate significantly less compared to established cell lines. Therefore, longer treatment times with test compounds may be required to assess their effect on proliferation.
14. Dilute test compounds in modified M87 medium to 2× the desired final concentration. Be certain to include proper vehicle (e.g., DMSO) and positive controls (e.g., cytotoxic compound for viability).
We have successfully used 20 μM doxorubicin or 1 μM staurosporine as a positive cytotoxic control in these assays.
15. Remove the plate from the incubator and add 75 to 100 μl of modified M87 medium containing 2× compound or controls to each well with a 12-channel pipettor to yield a final compound concentration of 1×. Perform an MTS endpoint viability assay 17. Defrost and prepare the MTS reagent according to the manufacturer's instructions for the Promega MTS Assay Kit. Transfer the MTS reagent to a 50-ml multi-channel pipetting reservoir.
18. Remove the plate from the incubator and, using a 12-channel pipettor, add 15 to 25 μl of the MTS reagent to each well (10% of the medium volume).
19. Incubate the cells for 1 to 5 hr at 37 • C in a 5% CO 2 humidified incubator until the vehicle control wells develop a dark red color. 20. Remove the plate from the incubator. Using a 12-channel pipettor, transfer 100 μl of the medium containing the MTS reagent to a new, clear, flat-bottom 96-well plate.
Models of Human
Read the absorbance at 490 nm using a plate reader, and normalize the absorbance values to the vehicle controls. As an example, organoids from a patient were treated with increasing concentrations of valproic acid (Fig. 14.23.6A; Cohen et al., 2011 Coordinate tissue collection 1. Tissue collection staff checks the surgery schedule daily to identify participants and assign a "collection event number" (de-identified number) that is not directly associated with patient information as required by Health Insurance Portability and Accountability Act (HIPAA) regulations. This ensures that researchers will not be able to identify the patient with this number. The tissue collection staff also reviews and notes the patient history and the clinical diagnosis.
Models of Human Breast Cancer
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Supplement 60 Current Protocols in Pharmacology 2. A tissue collection coordinator alerts the surgeon(s), pathologist(s), investigator(s) and tissue repository staff by e-mail 24 hr prior to surgery.
3. Informed consent must be obtained from the patient prior to the tissue collection. This is typically handled by either a nurse or other qualified hospital staff member.
4. Prior to the surgical procedure, the repository technician communicates with the operating room staff that a specimen for research has been planned.
5. The operating room staff notifies the tissue repository technician 10 min prior to when the tissue is removed from the patient. This is to ensure the repository technician can get to the operating room before the tissue is removed from the patient in order to minimize the amount of time to processing (see Tissue Sample Quality Control).
6. When the breast tissue is removed, the technician notes the time of day, and places the tissue into a container on ice for immediate transport to the pathology laboratory. The specimen is potentially infectious and must be handled with safety considerations appropriate for tissue bearing blood-borne pathogens.
7. The pathologist verifies the patient identification, and removes surplus tumor and adjacent uninvolved (normal) tissue for research.
8. Cryovials are labeled with the pre-assigned, de-identified number. The tissue type (cancerous or adjacent uninvolved), location within the breast from where the tissue was removed, and procurement time are noted on a specimen worksheet. 11. If the remaining tumor specimen is a minimum of 100 mg (300 mg minimum for grossly uninvolved normal tissue), place the tissues into separate 50-ml conical tubes containing RPMI for immediate tissue implantation or disassociation to organoids. If the specimens are smaller, the tissue is generally not processed into viable cells due to low yields of viable cells. If the minimum amount of tissue is not available for viable cell processing, the remaining tissue is processed as described in steps 9 and 10, as necessary.
12. Enter patient identification, specimen collection information, and storage information into a biospecimen tracking database such as the itBioPath Biospecimen Management System (see itBioPath Biospecimen Management System, below).
13. The itBio Path Biospecimen Management system subsequently generates a new deidentified number for each specimen type (RNA, organoids, tissue, etc.) associated with that specific patient/collection. The second number is utilized to separately track each specimen type. Barcode labels are generated with the de-identified number and are placed on each cryovial. This number is linked in a de-identified manner to subsequent processing and/or clinical and pathological follow-up information. The itBioPath System complements and enables high quality patient-derived research with the following capabilities:
Tracks specimen collections, processing and storage information, banked specimen availability for originating specimens, succeeding xenograft transformations, and related specimen products. Provides multigenerational bidirectional linkage of specimen transformations, including the relationship to the originating patient specimen, annotations, and consents. Provides separation of patient specimen and xenograft specimen pathology annotations. Integrates with genomic experimentation data in the HCI Research Informatics' GNomEx product suite. Integrates with the University of Utah Health Sciences Electronic Data Warehouse for access to clinical information. Integrates with a patient-centric system for Cancer Clinical Research (CCR) for capturing information on patients being treated in the multidisciplinary teams, and others. Captures chronological and audit documentation of specimen management and disbursement activities. Allows for batch data entry capabilities to ensure high quality data collection. Controls security of data access for each user dependent on protocol requirements and the role of the user interacting with the data. Offers user designed Ad Hoc queries for full data retrieval.
Tissue sample quality control
The quality of nucleic acid or cell preparations from tissue depends greatly on the quality of the tissue. In particular, the time required for tissue procurement after removal from the patient should be minimized to limit hypoxic effects that can cause loss of tissue integrity. If the key personnel are aware that collection times are being annotated, the collection typically proceeds quickly.
14. Always record the procurement time from excision of tissue to freezing or fixation.
It is strongly recommended that processing be completed within 20 to 30 min.
15. Before utilizing the RNA, always determine the quality using an instrument such as the Agilent 2100 Bioanalyzer. 
PREPARATION OF ESTROGEN PELLETS
Estrogen pellets are made in-house and are a less expensive reliable alternative to purchasing them commercially. These pellets are designed to last up to 1 year in mice; however, we typically replace after 6 months.
Materials
Beeswax (Sigma, cat. no 6. Collect the solidified pellets into sterile 1.5-ml microcentrifuge tubes and store up to 6 months at 4 • C.
SUPPORT PROTOCOL 3
PREPARATION OF GROWTH FACTOR-REDUCED EHS MATRIX
Growth factor-reduced Matrigel is available from BD Biosciences (cat. no. 54230). Matrigel (EHS matrix) is composed of extracellular matrix derived from EnglebrethHolm-Swarm (EHS) tumors. Large amounts of EHS matrix can be produced in the laboratory at minimal cost; production of the matrix in the laboratory also allows a single lot to be used for many experiments, which reduces lot-to-lot variability. The following protocol, which is modified from a published procedure (Kibbey, 1994) , details a method to generate EHS matrix. The EHS matrix is obtained by xenografting the EHS cell line (ATCC #CRL-2108) according to the manufacturer's instructions. Xenografted EHS tumors can be flash frozen and stored at −80 • C until needed.
Materials
10 g Englebreth-Holm-Swarm (EHS) sarcoma tumor tissue isolated from mice (ATCC #CRL-2108) 3.4 M NaCl buffer (see recipe) 2 M urea buffer (see recipe) Tris-buffered saline (TBS; see recipe) Ammonium sulfate powder (Sigma, cat. no Snap closures for dialysis tubing 1-liter glass beakers DMEM medium with high glucose and L-glutamine (Invitrogen, cat. no. 11965-092) Scissors and hemostat, sterilized 15-ml conical tubes, sterile NOTE: It is important that every step of the protocol be conducted on ice or at 4 • C, or the solutions will solidify and the entire batch will be unusable.
1. Thaw 10 g of EHS tumor tissue on ice in a 50-ml Nalgene centrifuge bottle (takes ∼3 hr).
2. Add 30 ml (3 ml buffer/g tumor) of cold 3.4 M NaCl buffer to the centrifuge tube. Use an electric tissue homogenizer (PowerGen 125) to homogenize the tumor tissue at high speed (setting 6) until the tissue dissolves into a slurry.
3. Place the Nalgene tubes containing the tumor homogenate in a JA-25.50 rotor (Beckman), balance, and centrifuge 15 min at 8000 × g, 4 • C. Discard the supernatant.
4. Add 30 ml of the 3.4 M NaCl buffer to the tube. Electrically homogenize the tumor pellets again at high speed (setting 6) until the pellet dissolves into a slurry.
5. Balance the tube, and centrifuge 15 min at 8000 × g, 4 • C. Discard the supernatant.
6. Repeat steps 4 and 5.
7. Add 1 ml per g of original tissue of cold 2 M urea buffer to the tube. Electrically homogenize the tumor pellets at high speed (setting 6) until the pellet dissolves into a slurry.
8. Transfer the mixture to a 250-ml Nalgene centrifuge tube. Add a 1.5-in. magnetic stir bar and stir at a medium speed (5 on a scale of 10) overnight at 4 • C on a stir plate.
9. Centrifuge mixture 20 min at 23,708 × g, 4 • C. Save supernatant.
10. Add 0.5 ml per g of original tissue of cold 2 M urea buffer to the tube. Electrically homogenize the tumor pellets at high speed until the pellet dissolves into a slurry.
11. Centrifuge the mixture 20 min at 23,708 × g, 4 • C. Save supernatant.
12. Combine supernatants from steps 9 and 11 (14 ml) and place the supernatants in dialysis tubing. Seal the dialysis tube with a snap closure.
13. Add at least 10 volumes of cold TBS to a 1-liter glass beaker. Place the dialysis tubing in the beaker with a 1.5-in. magnetic stir bar. Subsequently dialyze by stirring the TBS solution at medium speed (5 out of 10) for 2 hr. Repeat at least two additional times with fresh buffer, for a total of at least 6 hr of dialysis with at least three buffer changes.
14. Empty the dialysis bags into a 250-ml Nalgene centrifuge bottle with a stir bar and add 20% (w/v) ammonium sulfate powder (about 16.4g/100 ml, 2.296 g in this case) slowly while stirring at a medium speed (setting 5 on a scale of 10) until all the (NH 4 ) 2 SO 4 is dissolved, then stir at medium speed for 1 hr.
15. Collect the precipitate by centrifugation for 15 min at 7000 × g, 4 • C. Discard the supernatant.
16. Add 14 ml of cold TBS and homogenize the pellet at high speed (setting 6) until the pellet breaks up into a slurry. Add a stir bar and stir at medium speed (5 on a scale of 10) until the slurry dissolves.
Models of Human Breast Cancer
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Supplement 60 Current Protocols in Pharmacology 17. Transfer the solution to dialysis tubing and seal the tube with a snap closure. Add at least 10 volumes of cold TBS to a 1-liter glass beaker. Place the dialysis tubing in the beaker with a 1.5-in. stir bar. Subsequently dialyze by stirring the TBS solution at medium speed (5 on a scale of 10) for 2 hr. Repeat the dialysis with fresh TBS for at least 2 more hr.
18. Repeat steps 14 and 15.
19. Add 7 ml of cold TBS and homogenize the pellet at high speed (setting 6) until the pellet breaks up into a slurry. Add a stir bar and stir at medium speed (5 on a scale of 10) until the slurry dissolves.
20. Transfer the solution to dialysis tubing and seal the tube with a snap closure. Add at least 10 volumes of cold TBS containing 5 ml chloroform per liter to a 1-liter glass beaker. Place the dialysis tubing in the beaker with a 1.5-in. stir bar. Subsequently dialyze by stirring the TBS/chloroform solution at medium speed (5 on a scale of 10) until the mixture becomes clear, which typically can take between 2 and 10 hr.
A glass container or cylinder must be used since the solution contains chloroform, which is utilized to sterilize the mixture.
21. After the mixture is no longer cloudy, remove the dialysis bag, clean the container thoroughly to remove the chloroform, and continually dialyze for at least 2 hr against at least 10 vol of cold TBS with stirring at a medium speed (5 out of 10). Repeat the dialysis at least three more times with fresh buffer, for a total of at least 8 hr of dialysis with at least four buffer changes.
22. Perform the final dialysis against at least 10 vol of DMEM medium in a 1-liter glass beaker with medium stirring (5 on a scale of 10) overnight at 4 • C.
23. In a biosafety cabinet, spray the outside of the dialysis bag with 70% ethanol then open and hold the bag with sterile scissors and hemostats.
24. Remove the EHS matrix with a sterile pipet and/or pour it into a sterile 15-ml conical tube on ice. Aliquot the matrix into sterile 1.5-ml microcentrifuge tubes on ice.
This protocol typically generates a final EHS matrix protein concentration of 6 to 7 mg/ml. The aliquots can be stored at 4
• C for up to 1 month or at −20
• C for up to 1 year. Make sure to thaw frozen aliquots at 4
• C. 
REAGENTS AND SOLUTIONS
Collagenase enzyme stock (10×)
For human tumors: Prepare 20 mg/ml Type 3 collagenase (Worthington, cat. no. LS004182) in Dulbecco's phosphate-buffered saline (DPBS; Invitrogen, cat. no. 14040-141). Filter sterilize and store in aliquots at −20 • C for up to 1 year.
For xenografted or murine tumors: Prepare 10 mg/ml Type IV collagenase (Sigma, cat. no. C5138) in digestion buffer (for xenografted or murine tumors; see recipe). Filter sterilize and store in aliquots at −20 • C for up to 1 year. 10 mM HEPES (Sigma, cat. no. H3537) 2% bovine serum albumin (BSA, Sigma, cat. no. A7906) 5 μg/ml insulin (with transferrin/selenium, Invitrogen, cat. no. 51500-056) 0.5 μg/ml hydrocortisone (Sigma, cat. no 
Digestion buffer
Human breast epithelial cell (HBEC) medium
Hyclone DMEM/F12 (1:1) with HEPES (Thermo Scientific, cat. no. SH30023.01) supplemented with: 10 mM HEPES (Sigma, cat. no. H3537) 5% (v/v) fetal bovine serum (FBS, Sigma, cat. no. F6178) 1 mg/ml bovine serum albumin (BSA, Sigma, cat. no. A7906) 1 μg/ml insulin (with transferrin/selenium, Invitrogen, cat. no. 51500-056) 0.5 μg/ml hydrocortisone (Sigma, cat. no. H0888) 50 μg/ml gentamycin (HyClone, cat. no. 3V30080.01) 2.5 μg/ml Fungizone (Amphotericin B, HyClone, cat. no. SV30078.01) Filter sterilize Store up to 30 days at 4
• C
Hyaluronidase enzyme stock (100×)
Prepare hyaluronidase (Sigma, cat. no . H3884) at 10,000 U/ml in Dulbecco's phosphate-buffered saline (DPBS; Invitrogen, cat. no. 14040-141) . Filter sterilize and store at −20 • C for up to 1 year.
Lidocaine-bupivacaine mixture
5 mg/ml Lidocaine (Hospira, cat. no. 0409-2066-05; http://www.hospira.com) 2.5 mg/ml Bupivacaine (available at pharmacies) Dilute in HBSS (Thermo Scientific, cat. no. SH30268.02) Filter sterilize, aliquot in 1.5-ml microcentrifuge tubes and store at room temperature until the expiration date listed on the lidocaine and bupivacaine samples
Modified M87 medium
Prepare fresh stocks of the different medium components described in Table 14 .23.4 using sterile technique. The stock solutions can be stored for up to 1 month at −20 • C, except cholera toxin and T3, which are stored at 4 • C.
continued
TAC solution (1×)
Mix 1 part of 170 mM Tris buffer, pH 7.4 (see recipe) with 9 parts of 150 mM NH 4 Cl, pH 7.4. Filter sterilize and store at room temperature for up to 6 months. 
COMMENTARY
Background Information
Patient-derived tumorgrafts growing in mice can recapitulate clinical manifestations and pathological features of a patient's original tumor, including its histology, molecular subtype, genomic organization, and metastatic dissemination (DeRose et al., 2011) . Thus, mice carrying primary tumorgrafts are ideal experimental models for studying the in vivo events of human tumorigenesis and for assessing the efficacy of investigational compounds in diverse cancer subtypes. Tumorgrafting also provides a method to propagate patient-derived tissue for more extensive in vivo and in vitro studies. While the complicated methodology, cost, variability, and time requirements of tumorgrafting make this technique impractical for widespread adoption into the clinic, there are potential opportunities to apply tumorgrafts in future clinical practice. For example, tumorgrafts can provide diagnostic information on the aggressiveness of a patient's tumor [successful engraftment is associated with worse patient outcome (DeRose et al., 2011)] , and for functionally evaluating the sensitivity of tumors to specific drugs prior to treating patients. While tumorgrafts are getting traction in early translational research programs, significant barriers must still be overcome before they are practical for clinical applications.
A tumorgraft bank is an effective tool for many research purposes. Currently, the ratelimiting step is the initial investment, in both
